close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NextPoint Therapeutics

News headline image
NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics to Highlight Antibody-Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings Targeting Novel B7-H7 Pathway at AACR Annual Meeting
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health List
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive Officer
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific Officer
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid Tumors
From NextPoint Therapeutics
Via Business Wire
News headline image
Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer
From NextPoint Therapeutics
Via Business Wire
News headline image
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
From NextPoint Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today